Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.27
-0.4%
$10.62
$6.65
$12.61
$706.39M0.026,169 shs4,037 shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.21
+5.2%
$2.05
$1.15
$42.20
$101.45M-2.042.79 million shs1.55 million shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$4.76
+5.8%
$4.99
$0.13
$1.04
$91.67M1.581.05 million shs23,193 shs
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
C$0.00
C$14.01
C$36.02
C$10.76BN/A1.38 million shs1.23 million shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
+3.62%+3.36%-5.33%+28.55%+16.76%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
+1.45%-2.78%+1.45%+45.83%-78.06%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-4.26%-8.54%-6.05%+5.39%+1,446.39%
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.1359 of 5 stars
3.53.00.00.02.20.00.6
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
4.1633 of 5 stars
3.33.00.04.72.70.01.3
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
0.1115 of 5 stars
1.00.00.00.00.00.80.6
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00192.11% Upside
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,366.06% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.00
Hold$5.005.04% Upside
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.37$0.07 per share139.08$3.25 per share3.16
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A342.33N/A-4.14%-6.01%-3.23%7/31/2025 (Estimated)
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest VRX, VIRI, SAVA, and PHAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.15N/AN/AN/A$70.36 millionN/A
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million47.15 millionOptionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable
Valeant Pharmaceuticals International, Inc. stock logo
VRX
Valeant Pharmaceuticals International
N/A349.30 millionN/ANot Optionable

Recent News About These Companies

Valeant Pharma acquires Medicis for US $2.6 billion
SCOTUS Passes on Valeant's Challenge to False Claims Act Ruling
Kiniksa Pharmaceuticals International PLC Class A
Valeant Urges SCOTUS to Clarify Disclosure Rule in Fraud Law
Valeant Pharmaceuticals International, Inc. (VRX.TO)
Love Him or Hate Him, Ackman Now Runs the Worlds Top Hedge Fund
Branded Generics Global Market Report 2023
Despite Woes, Valeant May Be Headed for a Rebound
Valeant Pharmaceuticals International, Inc. (VRX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.27 -0.04 (-0.39%)
Closing price 03:56 PM Eastern
Extended Trading
$10.27 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.21 +0.11 (+5.24%)
Closing price 04:00 PM Eastern
Extended Trading
$2.24 +0.03 (+1.36%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$4.76 +0.26 (+5.78%)
As of 07/17/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Valeant Pharmaceuticals International stock logo

Valeant Pharmaceuticals International TSE:VRX

Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.